Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Polyrizon Ltd. ( (PLRZ) ) has shared an update.
On January 8, 2026, Polyrizon Ltd. announced it has completed the branding process for its PL-14 intranasal allergy blocker, which will be marketed under the name NASARIX™, marking a key step in preparing the product for future commercialization. The company conducted comprehensive trademark screening and linguistic evaluations across U.S. and European markets to support regulatory and market alignment, and management framed the new brand as central to building a strong identity in allergy and respiratory health as the PL-14 program advances toward clinical and regulatory milestones.
More about Polyrizon Ltd.
Polyrizon Ltd. is a pre-clinical-stage biotechnology company specializing in innovative intranasal medical device hydrogels delivered as nasal sprays, designed to form a thin protective barrier in the nasal cavity against viruses and allergens. Its proprietary Capture and Contain (C&C) hydrogel platform, and earlier-stage Trap and Target (T&T) technology for intranasal delivery of active pharmaceutical ingredients, position the company in the allergy and respiratory health markets with a focus on barrier-forming “biological mask” solutions.
Average Trading Volume: 3,147,885
Technical Sentiment Signal: Sell
Current Market Cap: $21.17M
See more data about PLRZ stock on TipRanks’ Stock Analysis page.